GLP-1 Manufacturing Evolution: Scaling Innovation for Injectable and Oral Therapies
Day 1 Manufacturing 5.0 Stage
06/10/2026 16:15 - 17:00pm
Contributors
Edgar A. Pogna : Principal - L.E.K. Consulting
Trishul Shah : Founder and Principal - T5 Helix Advisory
Hoori Kaskanian : Global Head 'GLP-1' Platform - Sandoz AG
Oliver Haferbeck : Head of Business Unit Drug Delivery - Haselmeier, a medmix Brand
Riccardo Marcon : Senior Vice President, Sales & Marketing - DCS - Stevanato Group
The GLP-1 therapeutic class is reshaping pharmaceutical manufacturing, driven by explosive demand for injectable formulations and the emerging shift toward oral delivery formats. This panel will explore the multifaceted challenges and opportunities in scaling GLP-1 production, focusing on the technical, operational, and market dynamics that are defining this evolution.
Key discussion points include:
- Manufacturing Scale Challenges: Addressing the strain on production capacity and supply chains as demand for GLP-1 therapies surges globally.
- Oral Delivery Innovation: Examining the unique manufacturing requirements for oral GLP-1 formats, including higher API volumes, specialised excipients, and advanced tableting processes.
- Market Access and Cost Optimisation: Exploring how manufacturing efficiencies can reduce costs and expand access to GLP-1 therapies for broader patient populations.
We are recruiting participants across the industry: Big-Pharma, SMID, CDMOs, device manufacturers, Industry leaders, etc.